Voltar
Revisão
BIBTEX RIS

Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study

1997; Wiley; Volume: 79; Issue: S1 Linguagem: Inglês

10.1111/j.1464-410x.1997.tb00795.x

ISSN

1365-2176

Autores

Rosalind A. Eeles, David P. Dearnaley, Audrey Ardern‐Jones, Robert Shearer, Douglas F. Easton, Deborah Ford, Stephen M. Edwards, Anna Dowe,

Tópico(s)

Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities

Resumo

British Journal of UrologyVolume 79, Issue S1 p. 8-14 Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study R.A. EELES FRCR, Corresponding Author R.A. EELES FRCR Senior Lecturer and Honorary Consultant Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UK Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UK D.P. Dearnaley, FRCR in Cancer Genetics and Oncology, Senior Lecturer and Honorary Consultant.Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. Tel: +44 181 642 6011 × 3523, Fax: +44 181 770 1489. E-mail: [email protected]Search for more papers by this authorD.P. DEARNALEY, D.P. DEARNALEY Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UK Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UK D.P. Dearnaley, FRCR in Cancer Genetics and Oncology, Senior Lecturer and Honorary Consultant.Search for more papers by this authorA. ARDERN-JONES, A. ARDERN-JONES Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UK A. Ardern-Jones, DipN Clinical Nurse Specialist in Cancer Genetics.Search for more papers by this authorR.J. SHEARER FRCS, R.J. SHEARER FRCS Consultant Surgeon Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this authorD.F. EASTON, D.F. EASTON CRC Unit of Genetic Epidemiology, Institute of Public Health, Cambridge, UK D.F. Easton, PhD, Director, CRC Genetic Epidemiology Unit.Search for more papers by this authorD. FORD MSc, D. FORD MSc Statistician Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this authorS. EDWARDS BSc, S. EDWARDS BSc Molecular Scientist Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this authorA. DOWE, A. DOWE Research Nurse Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this author105 collaborators, 105 collaboratorsSearch for more papers by this author R.A. EELES FRCR, Corresponding Author R.A. EELES FRCR Senior Lecturer and Honorary Consultant Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UK Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UK D.P. Dearnaley, FRCR in Cancer Genetics and Oncology, Senior Lecturer and Honorary Consultant.Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK. Tel: +44 181 642 6011 × 3523, Fax: +44 181 770 1489. E-mail: [email protected]Search for more papers by this authorD.P. DEARNALEY, D.P. DEARNALEY Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UK Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UK D.P. Dearnaley, FRCR in Cancer Genetics and Oncology, Senior Lecturer and Honorary Consultant.Search for more papers by this authorA. ARDERN-JONES, A. ARDERN-JONES Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UK A. Ardern-Jones, DipN Clinical Nurse Specialist in Cancer Genetics.Search for more papers by this authorR.J. SHEARER FRCS, R.J. SHEARER FRCS Consultant Surgeon Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this authorD.F. EASTON, D.F. EASTON CRC Unit of Genetic Epidemiology, Institute of Public Health, Cambridge, UK D.F. Easton, PhD, Director, CRC Genetic Epidemiology Unit.Search for more papers by this authorD. FORD MSc, D. FORD MSc Statistician Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this authorS. EDWARDS BSc, S. EDWARDS BSc Molecular Scientist Institute of Cancer Research, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this authorA. DOWE, A. DOWE Research Nurse Royal Marsden Hospital, Downs Road, Sutton, Surrey, Institute of Public Health, Cambridge, UKSearch for more papers by this author105 collaborators, 105 collaboratorsSearch for more papers by this author First published: 14 July 2014 https://doi.org/10.1111/j.1464-410X.1997.tb00795.xCitations: 22 All collaborators are given the same position in this paper and are listed at the end. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Office of Population Censuses and Surveys. UK, HMSO, 1992. 2 American Cancer Society Statistics, USA, 1994. 3 Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARC, Lyon, France, 1993: ch. 21, p. 21. 4 Haas GP, Sakr W, Cassin B et al. The prevalence of prostate cancer in young black and white males. J Urol 1992; 147: 290A. 5 Woolf CM. An investigation of the familial aspects of carcinoma of the prostate. Cancer 1960; 13: 739– 44. 6 Morganti G, Gianferrari L, Cresseri A, Arrigoni G, Lorati G. Recherches clinico-statistiques et génétiques sur les néoplasies de la prostate. Acta Genetica Statistica 1959; 6: 304– 5. 7 Krain LS. Some epidemiologic variables in prostatic carcinoma in California. Prev Med 1974; 3: 154– 9. 8 Fincham SM, Hill GB, Hanson J, Wijayasinghe C. Epidemiology of prostate cancer: a case control study. Prostate 1990; 17: 189– 206. 9 Cannon LA, Bishop DT, Skolnick M, Hunt S, Lyon J, Smart C. Genetic epidemiology of prostate cancer in the Utah Mormon Genealogy. Cancer Surv 1982; 1: 47– 69. 10 Meikle AW, Smith JA, West DW. Familial factors affecting prostatic cancer risk and plasma sex-steroid levels. Prostate 1985; 6: 121– 8. 11 Isaacs SD, Lambertus ALMK, Baffoe-Bonnie A, Beaty TH, Walsh PC. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87: 991– 6. 12 Keetch DW, Rice JP, Suarez BK, Catalona WJ. Familial aspects of prostate cancer: a case control study. J Urol 1995; 154: 2100– 2. 13 Steele R, Lees REM, Kraus AS, Rao C. Sexual factors in the epidemiology of cancer of the prostate. J Chron Dis 1971; 24: 29– 37. 14 Schuman T, Mandel J, Blackard C, Bauer H, Scarlett J, McHugh R. Epidemiologic study of prostatic cancer: preliminary report. Cancer Treatment Reports 1977; 61: 181– 6. 15 Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337– 47. 16 Spitz MR, Currier RD, Fueger JJ, Babaian J, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991; 146: 1305– 7. 17 Ghadirian P, Cadotte M, Lacroix A, Perret C. Family aggregation of cancer of the prostate in Quebec: the tip of the iceberg. Prostate 1991; 19: 43– 52. 18 Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600– 8. 19 Gronberg H, Damber L, Damber JE. Familial prostate cancer in Sweden. Cancer 1996; 77: 138– 43. 20 Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367– 71. 21 Knudson AG. Hereditary cancer, oncogenes and antioncogenes. Cancer Res 1985; 45: 1437– 43. 22 Mulligan LM, Kwok JBJ, Healey CS et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458– 60. 23 Narod S, Dupont A, Cusan L et al. The impact of family history on early detection of prostate cancer. Nat Med 1995; 1: 99– 101. 24 Thiessen E. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 1974; 34: 1102– 7. 25 Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. Br Med J 1992; 305: 855– 7. 26 Macklin MT. The genetic basis of human mammary cancer. Proceedings of the Second National Cancer Conference. New York: American Cancer Society, 1954: 1074– 87. 27 Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992; 84: 1114– 17. 28 Sellars TA, Potter JD, Rich SS et al. Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. J Natl Cancer Inst 1994; 86: 1860– 5. 29 Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE and the Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343: 692– 5. 30 Carter BS, Bova GS, Beaty TH et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797– 802. 31 Zahm SH, Blair A, Holmes FF, Boysen CD, Robel RJ, Fraumeni JF Jr. A case-control study of soft tissue sarcoma. Am J Epid 1989; 130: 665– 74. 32 Cannon-Albright LA, Eeles RA. Progress in prostate cancer. Nat Genet 1995; 9: 336– 7. 33 Thorlacius S, Olafsdottir G, Tryggvadottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 1996; 13: 117– 19. 34 Navone NM, Troncosco P, Pisters LL et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993; 85: 1657– 69. 35 Bookstein R, Rio P, Madreperla SA et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate cancer. Proc Natl Acad Sci USA 1990; 87: 7762– 6. 36 Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation at the MXI1 gene in prostate cancer. Nat Genet 1995; 9: 249– 55. 37 Dong J-T, Lamb PW, Rinker-Schaeffer CW et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 884– 6. 38 Carter BS, Ewing CM, Ward WS et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990; 87: 8751– 5. 39 Bova GS, Carter BS, Bussemakers MJG et al. Homozygous deletion and frequent allele loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993; 53: 3869– 73. 40 Bergerheim USR, Kunimi K, Collins VP, Ekman P. Deletion mapping of chromosomes, 8, 10 and 16 in human prostate carcinoma. Gene Chromosom Cancer 1991; 3: 215– 20. 41 Latil A, Baron JC, Cussenot O et al. Genetic alterations in localized prostate cancer: identification of a common region of deletion on chromosome arm 18q. Gene Chromosom Cancer 1994; 11: 119– 25. 42 Gao X, Zacharek A, Salkowski A et al. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995; 55: 1002– 5. 43 Hollstein MC, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49– 53. 44 Dobashi Y, Shuin T, Tsuruga H, Uemura H, Torigoe S, Kubota Y. DNA polymerase β gene mutation in human prostate cancer. Cancer Res 1994; 54: 2827– 9. 45 Ichikawa T, Niheii N, Suzuki H et al. Suppression of metastasis of rat prostatic cancer by introducing human chromosome 8, Cancer Res 1994; 54: 2299– 302. 46 Ichikawa T, Ichikawa Y, Dong J et al. Localisation of metastasis suppressor gene (s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 1992; 52: 3486– 90. 47 Berube NG, Speevak MD, Chevrette M. Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del (12) (q13). Cancer Res 1994; 54: 3077– 81. 48 Smith JR, Freije D, Carpten JD et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371– 4. 49 Sleddens HFBM, Oostra BA, Brinkmann AO et al. Trinucleotide repeat polymorphism in the androgen receptor gene. Hum Mol Genet 1993; 2: 273. 50 Coetzee GA, Ross RK. Prostate cancer and the androgen receptor. J Natl Cancer Inst 1994; 86: 872– 3. 51 Irvine RA, Yu MC, Ross RK, Coetzee GA, The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937– 40. Citing Literature Volume79, IssueS1March 1997Pages 8-14 ReferencesRelatedInformation

Referência(s)